Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation*

Pediatric Critical Care Medicine

Volumn 11, Issue 1, 2010, Pages 98-102

  Niebler, Robert A ^a   Punzalan, Rowena C ^a,c   Marchan, Marisela ^c   Lankiewicz, Michael W ^b,c  

^a Department of Pediatrics ^*  (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Complications; Extracorporeal membrane oxygenation; Factor VIIa; Hemorrhage; Thromboembolism; Thrombosis

Indexed keywords

APROTININ; DESMOPRESSIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ANALYTICAL PARAMETERS; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CASE STUDY; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; EXTRACORPOREAL OXYGENATION; HUMAN; INFANT; INTENSIVE CARE UNIT; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE DRUG DOSE; SURVIVAL; THROMBOEMBOLISM; TUBE;

EID: 75149154287     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181b0620b     Document Type: Article

References (20)

1. ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212
2. Butenas S, Brummel KE, Branda RF, et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923-930
3. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebocontrolled, double-blind clinical trials. J Trauma 2005; 59:8 -15; discussion 15-18
4. Shao YF, Yang JM, Chau GY, et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: A multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 2006; 191:245-249
5. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: A randomized, placebocontrolled, double-blind clinical trial. Anesthesiology 2005; 102:269-275
6. Diprose P, Herbertson MJ, O'Shaughnessy D, et al. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebocontrolled pilot study. Br J Anaesth 2005; 95:596-602
7. Brose S, Sirbu H, Engel M, et al. Successful use of recombinant factor VIIa in a patient with intractable bleeding during extracorporeal membrane oxygenation. Thorac Cardiovasc Surg 2005; 53:389-390
8. Dominguez TE, Mitchell M, Friess SH, et al. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2005; 6:348-351
9. Lopez-Herce Cid J, Arriola Pereda G, Zunzunegui Martinez JL, et al. Effectiveness of activated factor VII in postoperative bleeding after cardiac surgery with extracorporeal membrane oxygenation. An Pediatr (Barc) 2005; 62:471-474
10. Verrijckt A, Proulx F, Morneau S, et al. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 2004; 127:1812-1813
11. Wittenstein B, Ng C, Ravn H, et al. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med 2005; 6:473-476
12. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-298
13. Levi M, Peters M, Buller HR: Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med 2005; 33:883-890
14. Bui JD, Despotis GD, Trulock EP, et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002; 124:852-854
15. Velik-Salchner C, Sergi C, Fries D, et al. Use of recombinant factor VIIa (novoseven) in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporal membrane oxygenation. Anesth Analg 2005; 101:924
16. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55:638-648
17. Girard P, Nony P, Erhardtsen E, et al. Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thromb Haemost 1998; 80: 109-113
18. Riccabona M, Kuttnig-Haim M, Dacar D, et al. Venous thrombosis in and after extracorporeal membrane oxygenation: Detection and follow-up by color doppler sonography. Eur Radiol 1997; 7:1383-1386
19. Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 2007; 84:161-168
20. Veldman A, Neuhaeuser C, Akintuerk H, et al. rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Paediatr Anaesth 2007; 17:1176-1181